{"success":true,"data":{"pressRelease":{"id":"50614","rtpr_id":"nNFCjK5Qy","ticker":"ELTP","exchange":"OTC","all_tickers":["ELTP"],"title":"Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product","author":"Newsfile Corp","published_at":"2026-06-01T11:00:14.747Z","article_body":"Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite\nPharmaceuticals, Inc. (OTCQB: ELTP) (\"Elite\" or the \"Company\"), a specialty\npharmaceutical company engaged in the development, manufacture, and\ndistribution of niche generic products, today announced that it has submitted\nan Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug\nAdministration (FDA) for a generic drug product in the class of medications\ncalled anticoagulants.\n\nIQVIA reported branded product sales for the twelve months ending March 2026\nof $26 billion. There is no generic product on the market, and the brand has\nunexpired patents and exclusivity listed in the FDA's Approved Drug Products\nwith Therapeutic Equivalence (Orange Book). FDA approval and commercialization\nof a generic product depend on successful filing, FDA approval and addressing\nthe unexpired patents and exclusivities.\n\nAbout Elite Pharmaceuticals, Inc.\n\nElite Pharmaceuticals, Inc. is a specialty pharmaceutical company that\ndevelops, manufactures, and distributes niche generic products. Elite's\nproduct lines consist of immediate-release and controlled-release, solid oral\ndose products, which are marketed under the Elite Laboratories label, as well\nas pursuant to licenses granted to third-party pharmaceutical marketing and\ndistribution organizations. Elite operates a cGMP and DEA registered facility\nfor research, development, and manufacturing located in Northvale, NJ. For\nmore information, visit www.elitepharma.com.\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including, without\nlimitation, those related to the effects, if any, on future results,\nperformance or other expectations that may have some correlation to the\nsubject matter of this press release. Readers are cautioned that such\nforward-looking statements involve, without limitation, risks, uncertainties,\nand other factors not under the control of Elite, which may cause actual\nresults, performance or achievements of Elite to be materially different from\nthe results, performance or other expectations that may be implied by these\nforward-looking statements. These forward-looking statements may include\nstatements regarding the expected timing of approval, if at all, of products\nby the FDA and the actions the FDA may require of Elite in order to obtain\nsuch approvals. These forward-looking statements are not guarantees of future\naction or performance. These risks and other factors are discussed, without\nlimitation, in Elite's filings with the Securities and Exchange Commission,\nincluding its reports on forms 10-K, 10-Q, and 8-K. Elite is under no\nobligation to update or alter its forward-looking statements, whether as a\nresult of new information, future events or otherwise.\n\nContact:\n\nElite Pharmaceuticals, Inc.\nDianne Will, Investor Relations\n518-398-6222\nDianne@elitepharma.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/299559","article_body_html":"","raw_payload":{"data":{"id":"nNFCjK5Qy","title":"Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product","author":"Newsfile Corp","ticker":"ELTP","created":"2026-06-01T11:00:14.747Z","tickers":["ELTP"],"exchange":"OTC","article_body":"Northvale, New Jersey--(Newsfile Corp. - June 1, 2026) - Elite\nPharmaceuticals, Inc. (OTCQB: ELTP) (\"Elite\" or the \"Company\"), a specialty\npharmaceutical company engaged in the development, manufacture, and\ndistribution of niche generic products, today announced that it has submitted\nan Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug\nAdministration (FDA) for a generic drug product in the class of medications\ncalled anticoagulants.\n\nIQVIA reported branded product sales for the twelve months ending March 2026\nof $26 billion. There is no generic product on the market, and the brand has\nunexpired patents and exclusivity listed in the FDA's Approved Drug Products\nwith Therapeutic Equivalence (Orange Book). FDA approval and commercialization\nof a generic product depend on successful filing, FDA approval and addressing\nthe unexpired patents and exclusivities.\n\nAbout Elite Pharmaceuticals, Inc.\n\nElite Pharmaceuticals, Inc. is a specialty pharmaceutical company that\ndevelops, manufactures, and distributes niche generic products. Elite's\nproduct lines consist of immediate-release and controlled-release, solid oral\ndose products, which are marketed under the Elite Laboratories label, as well\nas pursuant to licenses granted to third-party pharmaceutical marketing and\ndistribution organizations. Elite operates a cGMP and DEA registered facility\nfor research, development, and manufacturing located in Northvale, NJ. For\nmore information, visit www.elitepharma.com.\n\nThis press release contains \"forward-looking statements\" within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including, without\nlimitation, those related to the effects, if any, on future results,\nperformance or other expectations that may have some correlation to the\nsubject matter of this press release. Readers are cautioned that such\nforward-looking statements involve, without limitation, risks, uncertainties,\nand other factors not under the control of Elite, which may cause actual\nresults, performance or achievements of Elite to be materially different from\nthe results, performance or other expectations that may be implied by these\nforward-looking statements. These forward-looking statements may include\nstatements regarding the expected timing of approval, if at all, of products\nby the FDA and the actions the FDA may require of Elite in order to obtain\nsuch approvals. These forward-looking statements are not guarantees of future\naction or performance. These risks and other factors are discussed, without\nlimitation, in Elite's filings with the Securities and Exchange Commission,\nincluding its reports on forms 10-K, 10-Q, and 8-K. Elite is under no\nobligation to update or alter its forward-looking statements, whether as a\nresult of new information, future events or otherwise.\n\nContact:\n\nElite Pharmaceuticals, Inc.\nDianne Will, Investor Relations\n518-398-6222\nDianne@elitepharma.com\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/299559"},"type":"article","timestamp":"2026-06-01T11:00:14.806634296Z","server_sent_at_ms":1780311614806},"received_at":"2026-06-01T11:00:14.857Z","source_url":"https://www.newsfilecorp.com/release/299559"},"analysis":{"id":"40046","press_release_id":"50614","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Commercialization dependent on overcoming unexpired patents and exclusivities","Forward-looking statements regarding approval timing are not guarantees"],"eventType":"regulatory","narrative":"Elite Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product.\n\nThe branded version of this drug generated $26 billion in sales over the trailing twelve months, according to IQVIA data.\n\nHowever, no generic version is currently on the market, and the brand retains unexpired patents and exclusivities listed in the FDA Orange Book, meaning commercialization is not immediate.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"ANDA filing for high-revenue generic target, but patent hurdles remain."},"keyFigures":{"customDimensions":{"branded_product_sales":"$26 billion"}},"quotedText":"There is no generic product on the market, and the brand has unexpired patents and exclusivity listed in the FDA's Approved Drug Products with Therapeutic Equivalence (Orange Book).","namedEntities":{"people":[{"name":"Dianne Will","role":"Investor Relations"}],"products":["generic anticoagulant","Elite Laboratories"],"companies":[{"name":"Elite Pharmaceuticals, Inc.","ticker":"ELTP"},{"name":"IQVIA","relationship":"data source"},{"name":"FDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"$26 billion","context":"branded product sales for the twelve months ending March 2026"}]},"materialImpact":{"score":2,"reasoning":"Filing of an ANDA is a standard procedural step in the generic drug development lifecycle. While it signals progress, commercialization is contingent on FDA approval and navigating unexpired patents/exclusivities, which introduces significant uncertainty and delay. It is not a binary approval event."},"tickerRelevance":{"others":[],"primary":"ELTP"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap/OTC","eventGravity":"regulatory_filing","sectorWeight":"Health Care","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Elite Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant product.\n\nThe branded version of this drug generated $26 billion in sales over the trailing twelve months, according to IQVIA data.\n\nHowever, no generic version is currently on the market, and the brand retains unexpired patents and exclusivities listed in the FDA Orange Book, meaning commercialization is not immediate.","key_figures":{"customDimensions":{"branded_product_sales":"$26 billion"}},"named_entities":{"people":[{"name":"Dianne Will","role":"Investor Relations"}],"products":["generic anticoagulant","Elite Laboratories"],"companies":[{"name":"Elite Pharmaceuticals, Inc.","ticker":"ELTP"},{"name":"IQVIA","relationship":"data source"},{"name":"FDA","relationship":"regulator"}],"dollarAmounts":[{"amount":"$26 billion","context":"branded product sales for the twelve months ending March 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-01T11:13:49.537Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap/OTC","eventGravity":"regulatory_filing","sectorWeight":"Health Care","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":41031,"modelName":"george-droid-qwen-72b"}}